Prescribing overview
Cardalis combines benazepril and spironolactone for clinical congestive heart failure from atrioventricular valvular insufficiency in dogs, alongside other treatment. It is not a substitute for stabilizing pulmonary edema.
Cardalis combines benazepril and spironolactone for clinical congestive heart failure from atrioventricular valvular insufficiency in dogs, alongside other treatment. It is not a substitute for stabilizing pulmonary edema.
Key prescribing checks
- Confirm the indication, route, current weight, disease status and concurrent treatments before prescribing.
Uses by species
Approval and evidence apply to the named product, species, route and indication. An extra-label use requires its own prescribing assessment; a human indication is not an animal approval.
Dogs
FDA-approved canine combinationManagement of clinical signs of AVVI-associated congestive heart failure with concurrent therapy
US Cardalis canine chewables; begin after pulmonary edema is stabilized.
Use / indication source ↗Pharmacology & pharmacokinetics
Mechanism and clinical role
Benazeprilat inhibits ACE; spironolactone and its metabolites block aldosterone receptors. These act at different points in the renin–angiotensin–aldosterone system.
Absorption, distribution, metabolism and elimination
Both ingredients undergo extensive hepatic biotransformation.
SAFETY REFERENCE · PRODUCT & SPECIES SPECIFIC
Contraindications & cautions
Contraindications identify circumstances where the source says a product should not be used. Precautions call for assessment or monitoring. Interactions identify combinations to review. They are distinct categories; this summary does not replace a full interaction check or the current product label.
Cardalis
US Cardalis canine chewables; begin after pulmonary edema is stabilized.
Contraindications · when not to use
- Addison's disease, hyperkalemia, hyponatremia, component-class hypersensitivity, or concurrent NSAIDs in dogs with renal insufficiency.
Precautions & monitoring
- Use caution with hepatic dysfunction. Growing and reproductive dogs lack established safety. The US label did not evaluate concurrent pimobendan safety/effectiveness.
Selected product information; this is not a complete interaction or patient-specific prescribing assessment.
Safety sources checked: . Selected label information; independent veterinary or veterinary-pharmacy review remains pending. A label for dogs, cats, horses or humans does not establish safety for another species.
Adverse effects
Renal insufficiency and potassium elevation were reported; disease progression can also cause clinical deterioration.
These are selected source-reported effects, not incidence estimates or an exhaustive list. Spontaneous postmarketing reports do not by themselves establish frequency or causality.
Dosing & administration
A verified veterinary dose has not been entered for this product. Human-label dosing must not be used as an animal regimen. Consult a current species-specific clinical source and the prescribing veterinarian.
No numeric regimen is supplied in this entry. The veterinarian must consult the exact current product label; this entry does not enable a dosing calculator.
Extra-label prescribing and food-animal residue requirements are separate from labeled regimens. FDA extra-label-use guidance ↗
Drug & supplement interactions
This monograph summarizes selected interactions. The comparison tool applies a curated set of rules and is not comprehensive. Reconcile prescription drugs, nonprescription products, supplements and recent treatment changes.
Compare with other medications and check species →
Cardalis
US Cardalis canine chewables; begin after pulmonary edema is stabilized.
- DOCP effects may be opposed; digoxin exposure may rise. Review NSAIDs and all separate benazepril or spironolactone prescriptions.
Monitoring
Check kidney function and potassium before initiation and regularly thereafter.
Client counseling
Give with food as prescribed. Bring every cardiac medication to review to prevent duplicate ingredients.
This section supports the veterinary team's discharge discussion; it does not replace the product’s Client Information Sheet where one is required.
Storage & handling
Store at controlled room temperature in secured packaging.
Brands, formulations & ingredient identity
Active ingredients
Benazepril · Spironolactone
Other searchable names: Cardalis · Spironolactone and benazepril hydrochloride
This reference is limited to the named product and presentation; matching ingredients do not establish interchangeability.
Shared ingredients do not establish interchangeable concentrations, routes, release properties, species labeling or regional availability.
Cardalis
- Formulation
- Canine fixed-ratio chewable tablets
- Label / product scope
- Dogs
US Cardalis canine chewables; begin after pulmonary edema is stabilized.
Product label / source ↗References & review status
Clinical reference updated October 27, 2026. Independent veterinary or veterinary-pharmacy review not yet completed. Evidence gaps remain explicitly identified; this page does not claim equivalence to a comprehensive, professionally reviewed veterinary formulary.
